L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote
May 14, 2024 05:53 ET
|
ALLIANCE PROMOTION MICROBIOTE
L'Alliance Promotion Microbiote devient l’European Microbiome Innovation for Health : une étape majeure pour structurer la filière d’excellence européenne du microbiote Paris - France – 14 mai...
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector
May 14, 2024 05:53 ET
|
ALLIANCE PROMOTION MICROBIOTE
The Alliance Promotion Microbiote is becoming the European Microbiome Innovation for Health: a major step towards structuring the European microbiome excellence sector Paris - France - May 14, 2024 -...
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
May 14, 2024 03:00 ET
|
Nouscom Srl
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that...
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024 16:00 ET
|
Fractyl Health, Inc.
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions
May 13, 2024 09:00 ET
|
Beacon Biosignals
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals announced a strategic partnership with Longboard Pharmaceuticals, Inc. that combines Longboard’s drug development expertise with Beacon’s...
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
May 13, 2024 08:00 ET
|
Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024 07:00 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio announces financial results and business highlights for the first quarter ended March 31, 2024
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 13, 2024 06:05 ET
|
AC Immune SA
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024
May 13, 2024 05:30 ET
|
Hummingbird Bioscience
Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.